IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors

Future Oncology

Volumn 5, Issue 3, 2009, Pages 305-308

  Rosell, Rafael ^a,b   Bertran Alamillo, Jordi ^b   Molina, Miguel Angel ^b   Taron, Miguel ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

Activating mutations; EGF receptor mutations; Gp130; IL6; K ras mutations; STAT3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GLYCOPROTEIN GP 130; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; STAT3 PROTEIN;

ARTICLE; AUTOCRINE EFFECT; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL RESEARCH; ENZYME ACTIVATION; GENE ACTIVATION; GENE DELETION; GENE OVEREXPRESSION; HUMAN; LIVER ADENOMA; LIVER TUMOR; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; NEOPLASM; PARACRINE SIGNALING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

EID: 66949122194     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.3     Document Type: Article

References (21)

1. Rebouissou S, Amessou M, Couchy G et al.: Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200-204 (2009).
2. Kishimoto T: Interleukin-6: from basic science to medicine - 40 years in immunology. Annu. Rev. Immunol. 23, 1-21 (2005).
3. Hodge DR, Hurt EM, Farrar WL: The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41, 2502-2512 (2005).
4. Grivennikov S, Karin M: Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13, 7-9 (2008).
5. Gao SP, Mark KG, Leslie K et al.: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest 117, 3846-3856 (2007).
6. Bollrath J, Phesse TJ, von Burstin VA et al.: gp130-mediated STAT3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associaced rumorigenesis. Cancer Cell 15, 91-102 (2009).
7. Anczile B, Lim KH, Counter CM: Oncogenic Ras-induced secretion of 1L-6 is required for tumorigenesis. Genes Dev. 21, 1714-1719 (2007).
8. Taron M, Ichinose Y, Rosell R et al.: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin. Cancer Res. 11, 5878-5885 (2005).
9. Cortes-Funes H, Gomez C, Rosell R et al.: Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer Patients. Ann. Oncol. 16, 1081-1086 (2005).
10. Mitsudomi T, Kosaka T, Endoh H et al.: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23, 2513-2520 (2005).
11. Han SW, Kim TY, Hwang PG et al.: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23, 2493-2501 (2005).
12. Takano T, Ohe Y, Sakamoto H et al.: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23, 6829-6837 (2005).
13. Shigematsu H, Lin L, Takahashi T et al.: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97, 339-346 (2005).
14. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64, 8919-8923 (2004).
15. Costa DB, Kobayashi S, Tenen DG, Huberman MS: Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58, 95-103 (2007).
16. Grivennikov S, Karin E, Terzic J et al.: IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113 (2009).
17. Judd LM, Bredin K, Kalantzis A, Jenkins BJ, Ernst M, Giraud AS: STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. Gastroenterology 131, 1073-1085 (2006).
18. Rigby RJ, Simmons JG, Greenhalgh CJ, Alexander WS, Lund PK: Suppressor of cytokine signalling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 26, 4833-4841 (2007).
19. Ernst M, Najdovska M, Grail D et al.: STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Invest. 118, 1727-1738 (2008).
20. Jenkins BJ, Grail D, Nheu T et al.: Hyperactivation of STAT3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling. Nat. Med. 11, 845-852 (2005).
21. Becker C, Fantini MC, Wirtz S et al.: IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4, 217-220 (2005).